Adrenal adrenoceptors in heart failure

Frontiers in Physiology

Volumn 5 JUL, Issue , 2014, Pages

  de Lucia, Claudio ^a   Femminella, Grazia D ^a   Gambino, Giuseppina ^a   Pagano, Gennaro ^a   Allocca, Elena ^a   Rengo, Carlo ^a,b   Silvestri, Candida ^a   Leosco, Dario ^a   Ferrara, Nicola ^a,b   Rengo, Giuseppe ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS   (Italy)

Author keywords

Adrenal gland; Adrenergic system; Catecholamine; Functional recovery; GRK2; Heart failure; adrenergic receptor

Indexed keywords

ACETYLCHOLINE; ADRENALIN; ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR KINASE 2; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; NICOTINIC RECEPTOR; NORADRENALIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ADRENAL GLAND; ADRENALIN RELEASE; CATECHOLAMINE RELEASE; CATECHOLAMINE SYNTHESIS; CHROMAFFIN CELL; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; NONHUMAN; NORADRENALIN RELEASE; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84904307770     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2014.00246     Document Type: Review

References (95)

1. CIBIS-II Investigators and Committees. (1999). The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353, 9-13.
2. Amadi, A., Ponikowski, P., and Coats, A. J. (1995). Role of catecholamines and sympathetic activation as a risk factor for coronary artery disease. J. Cardiovasc. Risk 2, 222-228.
3. Anavekar, N. S., and Solomon, S. D. (2005). Angiotensin II receptor blockade and ventricular remodelling. J. Renin Angiotensin Aldosterone Syst. 6, 43-48. doi: 10.3317/jraas.2005.006.
4. Anderson, G. H. Jr., Blakeman, N., and Streeten, D. H. (1994). The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J. Hypertens. 12, 609-615.
5. Armando, I., Jezova, M., Bregonzio, C., Baiardi, G., and Saavedra, J. M. (2004). Angiotensin II AT1 and AT2 receptor types regulate basal and stress-induced adrenomedullary catecholamine production through transcriptional regulation of tyrosine hydroxylase. Ann. N.Y. Acad. Sci. 1018, 302-309. doi: 10.1196/annals.1296.036.
6. Bathgate-Siryk, A., Dabul, S., Pandya, K., Walklett, K., Rengo, G., Cannavo, A., et al. (2014). Negative impact of beta-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms. Hypertension 63, 404-412. doi: 10.1161/HYPERTENSIONAHA.113.02043.
7. Becherer, U., Medart, M. R., Schirra, C., Krause, E., Stevens, D., and Rettig, J. (2012). Regulated exocytosis in chromaffin cells and cytotoxic T lymphocytes: how similar are they? Cell Calcium 52, 303-312. doi: 10.1016/j.ceca.2012.04.002.
8. Bergland, B. E. (1989). Pheochromocytoma presenting as shock. Am. J. Emerg. Med. 7, 44-48.
9. Berkowitz, D. E., Price, D. T., Bello, E. A., Page, S. O., and Schwinn, D. A. (1994). Localization of messenger RNA for three distinct alpha 2-adrenergic receptor subtypes in human tissues. Evidence for species heterogeneity and implications for human pharmacology. Anesthesiology 81, 1235-1244.
10. Brede, M., Nagy, G., Philipp, M., Sorensen, J. B., Lohse, M. J., and Hein, L. (2003). Differential control of adrenal and sympathetic catecholamine release by alpha 2-adrenoceptor subtypes. Mol. Endocrinol. 17, 1640-1646. doi: 10.1210/me.2003-0035.
11. Brede, M., Wiesmann, F., Jahns, R., Hadamek, K., Arnolt, C., Neubauer, S., et al. (2002). Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. Circulation 106, 2491-2496. doi: 10.1161/01.CIR.0000036600.39600.66.
12. Brum, P. C., Kosek, J., Patterson, A., Bernstein, D., and Kobilka, B. (2002). Abnormal cardiac function associated with sympathetic nervous system hyperactivity in mice. Am. J. Physiol. Heart Circ. Physiol. 283, H1838-H1845. doi: 10.1152/ajpheart.01063.2001.
13. Bylund, D. B., Eikenberg, D. C., Hieble, J. P., Langer, S. Z., Lefkowitz, R. J., Minneman, K. P., et al. (1994). International Union of pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 46, 121-136.
14. Cannon, W. B. (1963). Bodily Changes in Pain, Hunger, Fear and Rage, an Account of Researches into the Function of Emotional Excitement. New York, NY: Harper & Row.
15. Chen, M., Sato, P. Y., Chuprun, J. K., Peroutka, R. J., Otis, N. J., Ibetti, J., et al. (2013). Prodeath signaling of G protein-coupled receptor kinase 2 in cardiac myocytes after ischemic stress occurs via extracellular signal-regulated kinase-dependent heat shock protein 90-mediated mitochondrial targeting. Circ. Res. 112, 1121-1134. doi: 10.1161/CIRCRESAHA.112.300754.
16. Cohn, J. N., Levine, T. B., Olivari, M. T., Garberg, V., Lura, D., Francis, G. S., et al. (1984). Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311, 819-823.
17. Cortez, V., Santana, M., Marques, A. P., Mota, A., Rosmaninho-Salgado, J., and Cavadas, C. (2012). Regulation of catecholamine release in human adrenal chromaffin cells by beta-adrenoceptors. Neurochem. Int. 60, 387-393. doi: 10.1016/j.neuint.2011.12.018.
18. Davis, H. M., and Johnson, J. A. (2011). Heart failure pharmacogenetics: past, present, and future. Curr. Cardiol. Rep. 13, 175-184. doi: 10.1007/s11886-011-0181-6.
19. Ehrhart-Bornstein, M., Bornstein, S. R., Gonzalez-Hernandez, J., Holst, J. J., Waterman, M. R., and Scherbaum, W. A. (1995). Sympathoadrenal regulation of adrenocortical steroidogenesis. Endocr. Res. 21, 13-24.
20. Esler, M., Straznicky, N., Eikelis, N., Masuo, K., Lambert, G., and Lambert, E. (2006). Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 48, 787-796. doi: 10.1161/01.HYP.0000242642.42177.49.
21. Femminella, G. D., De Lucia, C., Iacotucci, P., Formisano, R., Petraglia, L., Allocca, E., et al. (2013a). Neuro-hormonal effects of physical activity in the elderly. Front. Physiol. 4:378. doi: 10.3389/fphys.2013.00378.
22. Femminella, G. D., Rengo, G., Pagano, G., De Lucia, C., Komici, K., Parisi, V., et al. (2013b). beta-adrenergic receptors and G protein-coupled receptor kinase-2 in Alzheimer's disease: a new paradigm for prognosis and therapy? J. Alzheimers. Dis. 34, 341-347. doi: 10.3233/JAD-121813.
23. Flugge, G., Van Kampen, M., Meyer, H., and Fuchs, E. (2003). Alpha2A and alpha2C-adrenoceptor regulation in the brain: alpha2A changes persist after chronic stress. Eur. J. Neurosci. 17, 917-928. doi: 10.1046/j.1460-9568.2003.02510.x.
24. Foley, C. M., McAllister, R. M., and Hasser, E. M. (2001). Thyroid status influences baroreflex function and autonomic contributions to arterial pressure and heart rate. Am. J. Physiol. Heart Circ. Physiol. 280, H2061-H2068.
25. Foucart, S., De Champlain, J., and Nadeau, R. (1988). In vivo interactions between prejunctional alpha 2- and beta 2-adrenoceptors at the level of the adrenal medulla. Can. J. Physiol. Pharmacol. 66, 1340-1343.
26. Fusco, A., Santulli, G., Sorriento, D., Cipolletta, E., Garbi, C., Dorn, G. W., et al. (2012). Mitochondrial localization unveils a novel role for GRK2 in organelle biogenesis. Cell. Signal. 24, 468-475. doi: 10.1016/j.cellsig.2011.09.026.
27. Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., et al. (2014). Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 129, e28-e292. doi: 10.1161/01.cir.0000441139.02102.80.
28. Grassi, G. (1998). Role of the sympathetic nervous system in human hypertension. J. Hypertens. 16, 1979-1987.
29. Grassi, G., Quarti-Trevano, F., Seravalle, G., and Dell'oro, R. (2007). Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. Nutr. Metab. Cardiovasc. Dis. 17, 473-481. doi: 10.1016/j.numecd.2007.01.004.
30. Grossini, E., Surico, D., Mary, D. A., Molinari, C., Surico, N., and Vacca, G. (2013). In anesthetized pigs human chorionic gonadotropin increases myocardial perfusion and function through a beta-adrenergic-related pathway and nitric oxide. J. Appl. Physiol. 115, 422-435. doi: 10.1152/japplphysiol.00425.2013.
31. Gurevich, E. V., Tesmer, J. J., Mushegian, A., and Gurevich, V. V. (2012). G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. Pharmacol. Ther. 133, 40-69. doi: 10.1016/j.pharmthera.2011.08.001.
32. Haase, M., Willenberg, H. S., and Bornstein, S. R. (2011). Update on the corticomedullary interaction in the adrenal gland. Endocr. Dev. 20, 28-37. doi: 10.1159/000321211.
33. Hausberg, M., Hillebrand, U., and Kisters, K. (2007). Addressing sympathetic overactivity in major depressive disorder. J. Hypertens. 25, 2004-2005. doi: 10.1097/HJH.0b013e3282ef9819.
34. Hein, L., Altman, J. D., and Kobilka, B. K. (1999). Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 402, 181-184.
35. Hodel, A. (2001). Effects of glucocorticoids on adrenal chromaffin cells. J. Neuroendocrinol. 13, 216-220. doi: 10.1046/j.1365-2826.2001.00628.x.
36. Huggett, R. J., Scott, E. M., Gilbey, S. G., Stoker, J. B., Mackintosh, A. F., and Mary, D. A. (2003). Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 108, 3097-3101. doi: 10.1161/01.CIR.0000103123.66264.FE.
37. Iaccarino, G., and Koch, W. J. (1999). Therapeutic potential of G-protein coupled receptor kinases in the heart. Expert Opin. Investig. Drugs 8, 545-554.
38. Iaccarino, G., Lefkowitz, R. J., and Koch, W. J. (1999). Myocardial G protein-coupled receptor kinases: implications for heart failure therapy. Proc. Assoc. Am. Physicians 111, 399-405.
39. Iaccarino, G., Tomhave, E. D., Lefkowitz, R. J., and Koch, W. J. (1998). Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. Circulation 98, 1783-1789.
40. Jewell-Motz, E. A., and Liggett, S. B. (1996). G protein-coupled receptor kinase specificity for phosphorylation and desensitization of alpha2-adrenergic receptor subtypes. J. Biol. Chem. 271, 18082-18087.
41. Kassim, T. A., Clarke, D. D., Mai, V. Q., Clyde, P. W., and Mohamed Shakir, K. M. (2008). Catecholamine-induced cardiomyopathy. Endocr. Pract. 14, 1137-1149. doi: 10.4158/EP.14.9.1137.
42. Kaye, D. M., Lefkovits, J., Jennings, G. L., Bergin, P., Broughton, A., and Esler, M. D. (1995). Adverse consequences of high sympathetic nervous activity in the failing human heart. J. Am. Coll. Cardiol. 26, 1257-1263.
43. Koch, W. J., Rockman, H. A., Samama, P., Hamilton, R. A., Bond, R. A., Milano, C. A., et al. (1995). Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 268, 1350-1353.
44. Leimbach, W. N. Jr., Wallin, B. G., Victor, R. G., Aylward, P. E., Sundlof, G., and Mark, A. L. (1986). Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 73, 913-919.
45. Lembo, P. M., Ghahremani, M. H., and Albert, P. R. (1999). Receptor selectivity of the cloned opossum G protein-coupled receptor kinase 2 (GRK2) in intact opossum kidney cells: role in desensitization of endogenous alpha2C-adrenergic but not serotonin 1B receptors. Mol. Endocrinol. 13, 138-147.
46. Link, R. E., Desai, K., Hein, L., Stevens, M. E., Chruscinski, A., Bernstein, D., et al. (1996). Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c. Science 273, 803-805.
47. Luttrell, L. M., and Lefkowitz, R. J. (2002). The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J. Cell Sci. 115, 455-465.
48. Lymperopoulos, A. (2013). Physiology and pharmacology of the cardiovascular adrenergic system. Front. Physiol. 4:240. doi: 10.3389/fphys.2013.00240.
49. Lymperopoulos, A., Rengo, G., Funakoshi, H., Eckhart, A. D., and Koch, W. J. (2007a). Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat. Med. 13, 315-323. doi: 10.1038/nm1553.
50. Lymperopoulos, A., Rengo, G., Gao, E., Ebert, S. N., Dorn, G. W. 2nd, and Koch, W. J. (2010). Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J. Biol. Chem. 285, 16378-16386. doi: 10.1074/jbc.M109.077859.
51. Lymperopoulos, A., Rengo, G., and Koch, W. J. (2007b). Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. Trends Mol. Med. 13, 503-511. doi: 10.1016/j.molmed.2007.10.005.
52. Lymperopoulos, A., Rengo, G., and Koch, W. J. (2012). GRK2 inhibition in heart failure: something old, something new. Curr. Pharm. Des. 18, 186-191. doi: 10.2174/138161212799040510.
53. Lymperopoulos, A., Rengo, G., and Koch, W. J. (2013). Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ. Res. 113, 739-753. doi: 10.1161/CIRCRESAHA.113.300308.
54. Lymperopoulos, A., Rengo, G., Zincarelli, C., Kim, J., and Koch, W. J. (2011). Adrenal beta-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels. J. Am. Coll. Cardiol. 57, 356-365. doi: 10.1016/j.jacc.2010.08.635.
55. Lymperopoulos, A., Rengo, G., Zincarelli, C., Kim, J., Soltys, S., and Koch, W. J. (2009). An adrenal beta-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 106, 5825-5830. doi: 10.1073/pnas.0811706106.
56. Lymperopoulos, A., Rengo, G., Zincarelli, C., Soltys, S., and Koch, W. J. (2008). Modulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activity. Mol. Ther. 16, 302-307. doi: 10.1038/sj.mt.6300371.
57. Macdonald, E., Kobilka, B. K., and Scheinin, M. (1997). Gene targeting-homing in on alpha 2-adrenoceptor-subtype function. Trends Pharmacol. Sci. 18, 211-219.
58. Masuo, K., Lambert, G. W., Esler, M. D., Rakugi, H., Ogihara, T., and Schlaich, M. P. (2010). The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hypertens. Res. 33, 521-528. doi: 10.1038/hr.2010.35.
59. Michel, M. C., and Rump, L. C. (1996). alpha-Adrenergic regulation of human renal function. Fundam. Clin. Pharmacol. 10, 493-503.
60. Narkiewicz, K., and Somers, V. K. (1997). The sympathetic nervous system and obstructive sleep apnea: implications for hypertension. J. Hypertens. 15, 1613-1619.
61. Nguyen, K., Kassimatis, T., and Lymperopoulos, A. (2011). Impaired desensitization of a human polymorphic alpha2B-adrenergic receptor variant enhances its sympatho-inhibitory activity in chromaffin cells. Cell Commun. Signal. 9, 5. doi: 10.1186/1478-811X-9-5.
62. Piao, L., Fang, Y. H., Parikh, K. S., Ryan, J. J., D'souza, K. M., Theccanat, T., et al. (2012). GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension. Circulation 126, 2859-2869. doi: 10.1161/CIRCULATIONAHA.
63. Port, J. D., and Bristow, M. R. (2001). Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J. Mol. Cell. Cardiol. 33, 887-905. doi: 10.1006/jmcc.2001.1358.
64. Prejbisz, A., Lenders, J. W., Eisenhofer, G., and Januszewicz, A. (2011). Cardiovascular manifestations of phaeochromocytoma. J. Hypertens. 29, 2049-2060. doi: 10.1053/ajem.2000.7341.
65. Radtke, W. E., Kazmier, F. J., Rutherford, B. D., and Sheps, S. G. (1975). Cardiovascular complications of pheochromocytoma crisis. Am. J. Cardiol. 35, 701-705. doi: 10.1016/0002-9149(75)90060-0.
66. Reiter, E., and Lefkowitz, R. J. (2006). GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol. Metab. 17, 159-165. doi: 10.1016/j.tem.2006.03.008.
67. Rengo, G., Galasso, G., Femminella, G. D., Parisi, V., Zincarelli, C., Pagano, G., et al. (2014). Reduction of lymphocyte G protein-coupled receptor kinase-2 (GRK2) after exercise training predicts survival in patients with heart failure. Eur. J. Prev. Cardiol. 21, 4-11. doi: 10.1177/2047487313491656.
68. Rengo, G., Leosco, D., Zincarelli, C., Marchese, M., Corbi, G., Liccardo, D., et al. (2010). Adrenal GRK2 lowering is an underlying mechanism for the beneficial sympathetic effects of exercise training in heart failure. Am. J. Physiol. Heart Circ. Physiol. 298, H2032-H2038. doi: 10.1152/ajpheart.00702.2009.
69. Rengo, G., Lymperopoulos, A., and Koch, W. J. (2009a). Future g protein-coupled receptor targets for treatment of heart failure. Curr. Treat. Options Cardiovasc. Med. 11, 328-338. doi: 10.1007/s11936-009-0033-5.
70. Rengo, G., Lymperopoulos, A., Zincarelli, C., Donniacuo, M., Soltys, S., Rabinowitz, J. E., et al. (2009b). Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 119, 89-98. doi: 10.1161/CIRCULATIONAHA.108.803999.
71. Rengo, G., Lymperopoulos, A., Zincarelli, C., Femminella, G., Liccardo, D., Pagano, G., et al. (2012a). Blockade of beta-adrenoceptors restores the GRK2-mediated adrenal alpha(2) -adrenoceptor-catecholamine production axis in heart failure. Br. J. Pharmacol. 166, 2430-2440. doi: 10.1111/j.1476-5381.2012.01972.x.
72. Rengo, G., Perrone-Filardi, P., Femminella, G. D., Liccardo, D., Zincarelli, C., De Lucia, C., et al. (2012b). Targeting the beta-adrenergic receptor system through G-protein-coupled receptor kinase 2: a new paradigm for therapy and prognostic evaluation in heart failure: from bench to bedside. Circ. Heart Fail. 5, 385-391. doi: 10.1161/CIRCHEARTFAILURE.112.966895.
73. Rengo, G., Zincarelli, C., Femminella, G. D., Liccardo, D., Pagano, G., De Lucia, C., et al. (2012c). Myocardial beta(2) -adrenoceptor gene delivery promotes coordinated cardiac adaptive remodelling and angiogenesis in heart failure. Br. J. Pharmacol. 166, 2348-2361. doi: 10.1111/j.1476-5381.2012.01954.x.
74. Rockman, H. A., Choi, D. J., Rahman, N. U., Akhter, S. A., Lefkowitz, R. J., and Koch, W. J. (1996). Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 93, 9954-9959. doi: 10.1073/pnas.93.18.9954.
75. Roghi, A., Pedrotti, P., Milazzo, A., Bonacina, E., and Bucciarelli-Ducci, C. (2011). Adrenergic myocarditis in pheochromocytoma. J. Cardiovasc. Magn. Reson. 13, 4. doi: 10.1186/1532-429X-13-4.
76. Sager, G., Trovik, T., Slordal, L., Jaeger, R., Prytz, P. S., Brox, J., et al. (1988). Catecholamine binding and concentrations in acute phase plasma after surgery. Scand. J. Clin. Lab. Invest. 48, 419-424. doi: 10.3109/00365518809085751.
77. Salazar, N. C., Vallejos, X., Siryk, A., Rengo, G., Cannavo, A., Liccardo, D., et al. (2013). GRK2 blockade with betaARKct is essential for cardiac beta2-adrenergic receptor signaling toward increased contractility. Cell Commun. Signal. 11, 64. doi: 10.1186/1478-811X-11-64.
78. Sallinen, J., Haapalinna, A., Macdonald, E., Viitamaa, T., Lahdesmaki, J., Rybnikova, E., et al. (1999). Genetic alteration of the alpha2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels. Mol. Psychiatry 4, 443-452. doi: 10.1038/sj.mp.4000543.
79. Schlaich, M. P., Lambert, E., Kaye, D. M., Krozowski, Z., Campbell, D. J., Lambert, G., et al. (2004). Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension 43, 169-175. doi: 10.1161/01.HYP.0000103160.35395.9E.
80. Schneider, J., Lother, A., Hein, L., and Gilsbach, R. (2011). Chronic cardiac pressure overload induces adrenal medulla hypertrophy and increased catecholamine synthesis. Basic Res. Cardiol. 106, 591-602. doi: 10.1007/s00395-011-0166-z.
81. Small, K. M., Forbes, S. L., Rahman, F. F., Bridges, K. M., and Liggett, S. B. (2000). A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J. Biol. Chem. 275, 23059-23064. doi: 10.1074/jbc.M000796200.
82. Small, K. M., Wagoner, L. E., Levin, A. M., Kardia, S. L., and Liggett, S. B. (2002). Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 347, 1135-1142. doi: 10.1056/NEJMoa020803.
83. Smith, P. A., Meaney, J. F., Graham, L. N., Stoker, J. B., Mackintosh, A. F., Mary, D. A., et al. (2004). Relationship of neurovascular compression to central sympathetic discharge and essential hypertension. J. Am. Coll. Cardiol. 43, 1453-1458. doi: 10.1016/j.jacc.2003.11.047.
84. Swedberg, K., Bristow, M. R., Cohn, J. N., Dargie, H., Straub, M., Wiltse, C., et al. (2002). Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 105, 1797-1803. doi: 10.1161/01.CIR.0000014212.04920.62.
85. Taraviras, S., Olli-Lahdesmaki, T., Lymperopoulos, A., Charitonidou, D., Mavroidis, M., Kallio, J., et al. (2002). Subtype-specific neuronal differentiation of PC12 cells transfected with alpha2-adrenergic receptors. Eur. J. Cell Biol. 81, 363-374. doi: 10.1078/0171-9335-00250.
86. Tseng, C. J., Chan, J. Y., Lo, W. C., and Jan, C. R. (2001). Modulation of catecholamine release by endogenous adenosine in the rat adrenal medulla. J. Biomed. Sci. 8, 389-394. doi: 10.1007/BF02255947.
87. Usui, I., Imamura, T., Babendure, J. L., Satoh, H., Lu, J. C., Hupfeld, C. J., et al. (2005). G protein-coupled receptor kinase 2 mediates endothelin-1-induced insulin resistance via the inhibition of both Galphaq/11 and insulin receptor substrate-1 pathways in 3T3-L1 adipocytes. Mol. Endocrinol. 19, 2760-2768. doi: 10.1210/me.2004-0429.
88. Von Lueder, T. G., and Krum, H. (2013). RAAS inhibitors and cardiovascular protection in large scale trials. Cardiovasc. Drugs Ther. 27, 171-179. doi: 10.1007/s10557-012-6424-y.
89. Wallace, D. J., Chen, C., and Marley, P. D. (2002). Histamine promotes excitability in bovine adrenal chromaffin cells by inhibiting an M-current. J. Physiol. 540, 921-939. doi: 10.1113/jphysiol.2001.013370.
90. Womble, J. R., Larson, D. F., Copeland, J. G., Brown, B. R., Haddox, M. K., and Russell, D. H. (1980). Adrenal medulla denervation prevents stress-induced epinephrine plasma elevation and cardiac hypertrophy. Life Sci. 27, 2417-2420. doi: 10.1016/0024-3205(80)90513-5.
91. Zaika, O. L., Pochynyuk, O. M., Kostyuk, P. G., Yavorskaya, E. N., and Lukyanetz, E. A. (2004). Acetylcholine-induced calcium signalling in adrenaline- and noradrenaline-containing adrenal chromaffin cells. Arch. Biochem. Biophys. 424, 23-32. doi: 10.1016/j.abb.2004.01.012.
92. Zincarelli, C., Soltys, S., Rengo, G., Koch, W. J., and Rabinowitz, J. E. (2010). Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. Clin. Transl. Sci. 3, 81-89. doi: 10.1111/j.1752-8062.2010.00190.x.
93. Zincarelli, C., Soltys, S., Rengo, G., and Rabinowitz, J. E. (2008). Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073-1080. doi: 10.1038/mt.2008.76.
94. Zolk, O., Quattek, J., Sitzler, G., Schrader, T., Nickenig, G., Schnabel, P., et al. (1999). Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation 99, 2118-2123. doi: 10.1161/01.CIR.99.16.2118.
95. Zysko, D., Gajek, J., Sciborski, R., Smereka, J., Checinski, I., and Mazurek, W. (2007). The pattern of activation of the sympathetic nervous system during tilt-induced syncope. Europace 9, 225-227. doi: 10.1093/europace/eum027.